| Code | CSB-RA008540MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of muIV.3 (clone IV.3), targeting FCGR2A (FcγRIIA; CD32A)—a low-affinity IgG Fc receptor that preferentially engages IgG immune complexes and helps trigger Fc-dependent cellular responses. FCGR2A/CD32A is broadly associated with myeloid-lineage immune cells and is also present on human platelets, linking antibody/immune-complex recognition to functions such as phagocytosis, inflammatory signaling, and platelet activation.
Clone IV.3 is widely used as a CD32/FCGR2A blocking antibody; it binds most strongly to the CD32 IIa isoforms and can be applied to reduce Fc receptor–mediated non-specific binding in antibody-based assays, as well as to probe FCGR2A-driven immune-complex biology in controlled systems. This biosimilar provides the antibody component alone, enabling researchers to investigate FcγRIIA engagement and downstream functional readouts (e.g., immune-complex–triggered responses and Fc-dependent assay behavior) without confounding variables from additional payloads or therapeutic combinations.
There are currently no reviews for this product.